A 10-K Annual Reports

Agilent Technologies, Inc. reported a 7% increase in net revenue to $6,948 million for the fiscal year ended October 31, 2025, compared to the previous year. This growth was driven by strong performance across all segments and geographic regions, with the Life Sciences and Diagnostics Markets segment showing particular strength with an 11% increase, partly due to the acquisition of BIOVECTRA. The company's net income remained stable at $1,303 million, favorably impacted by tax benefits. Agilent continued its focus on operational efficiency, including a restructuring initiative aimed at optimizing management structure and achieving cost savings. The company also actively managed its capital through share repurchases and dividend payments, demonstrating a commitment to shareholder returns. Despite the overall positive revenue trend, the company faced headwinds such as increased tariffs and shipping costs, which impacted gross margins. Agilent is actively implementing mitigation strategies to address these pressures. The company also highlighted its ongoing investment in research and development to maintain its competitive edge and expand its product and solution portfolios. Looking forward, Agilent remains optimistic about the long-term health of its key end markets, despite some customer funding uncertainties, and anticipates continued growth through strategic investments and market expansion.

Agilent Technologies, Inc. reported a 5% decrease in net revenue for the fiscal year ended October 31, 2024, reaching $6.51 billion. This decline was primarily attributed to weakened customer capital expenditure spending, impacting both the Life Sciences and Applied Markets and Diagnostics and Genomics segments, particularly within the pharmaceutical sector. However, the Agilent CrossLab segment demonstrated resilience with a 5% revenue increase, driven by strong demand for repair and maintenance services across all end markets. The company maintained profitability with net income of $1.29 billion, slightly up from the previous year, supported by cost-saving initiatives and higher interest income. Agilent also completed a significant acquisition of BIOVECTRA for $915 million, expanding its contract development and manufacturing capabilities. The company continues to focus on enhancing customer experience and driving productivity, anticipating a gradual recovery in customer capital budgets while managing inflationary pressures through pricing strategies and cost-saving measures.

Agilent Technologies, Inc. reported net revenue of $6.833 billion for the fiscal year ended October 31, 2023, a slight decrease compared to the prior year, primarily due to weaker demand in China and pressures on customer capital expenditures impacting the Life Sciences and Applied Markets segment. However, the Diagnostics and Genomics segment saw a slight increase, and the Agilent CrossLab services business demonstrated robust growth of 8%. The company incurred significant asset impairment charges of $270 million related to the exit of its Resolution Bioscience business, which impacted net income, though overall net income remained stable year-over-year at $1.240 billion. Agilent continued its focus on capital allocation, repurchasing $476 million of its stock under its 2023 repurchase program and paying $265 million in dividends. The company also announced a new restructuring plan in fiscal year 2023, involving a workforce reduction and facility consolidation, expected to yield $80 million in annual cost savings. Looking ahead, Agilent anticipates a challenging macroeconomic environment but remains optimistic about long-term growth opportunities across its key end markets.

Agilent Technologies, Inc. (Agilent) reported strong performance for the fiscal year ended October 31, 2022, with net revenue of $6.85 billion, an increase of 8% compared to the prior year, despite navigating challenges like supply chain pressures, inflation, and a COVID-related shutdown in China. All three business segments—Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab—experienced revenue growth. The company's financial health remains robust, with significant cash on hand and a strong operating margin of 23.6%. Agilent also demonstrated a commitment to shareholder returns through substantial share repurchases and consistent dividend payments. Looking ahead, Agilent anticipates continued inflationary and logistical pressures but remains optimistic about growth opportunities across its key end markets. The company continues to invest in research and development and strategic initiatives to enhance its product and service offerings, positioning itself for sustained long-term growth in the life sciences, diagnostics, and applied chemical markets.

Agilent Technologies, Inc. reported strong performance in its fiscal year ended October 31, 2021, with an 18% increase in net revenue to $6,319 million. This growth was driven by robust demand across all business segments – Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab – and key end markets, particularly pharmaceutical, chemical and energy, and diagnostics and clinical. The company successfully completed the acquisition of Resolution Bioscience, Inc., bolstering its precision oncology solutions. Financially, Agilent demonstrated strong operational leverage, with total operating margin increasing to 21.3%. The company continued to return value to shareholders through share repurchases and dividends, with $1.577 billion remaining authorization for share repurchases under its 2021 program. Agilent also maintained a strong liquidity position with $1,484 million in cash and cash equivalents, and no borrowings outstanding under its credit facilities. The company is well-positioned to navigate ongoing market dynamics, including supply chain pressures, and remains optimistic about long-term growth opportunities.

Agilent Technologies, Inc. reported for the fiscal year ended October 31, 2020, a 3% increase in net revenue to $5.339 billion, driven by a 4% rise in its Life Sciences and Applied Markets segment. This growth occurred despite the ongoing COVID-19 pandemic, which presented challenges such as unpredictable demand shifts, supply chain disruptions, and impacts on customer site access. The company also noted a 2% increase in its Diagnostics and Genomics business and a 3% increase in its Agilent CrossLab business. The company's net income for the year was $719 million, a decrease from the prior year, primarily due to the impact of the pandemic and an impairment charge of $98 million related to the closure of its sequencer development program. Agilent continued its commitment to returning capital to shareholders through share repurchases, with $469 million spent in 2020, and declared a quarterly dividend of $0.194 per share. The company maintains a strong liquidity position with $1.441 billion in cash and cash equivalents.

Agilent Technologies, Inc. reported solid performance in its fiscal year ended October 31, 2019. The company, a global leader in life sciences, diagnostics, and applied chemical markets, saw a 5% increase in net revenue to $5.163 billion, driven by growth in its Diagnostics and Genomics and Agilent CrossLab segments, which both increased by 8%. The Life Sciences and Applied Markets segment experienced a more modest 1% revenue increase. Acquisitions played a significant role in the company's growth, with the notable acquisitions of ACEA Biosciences and BioTek contributing positively to results, particularly in the cell analysis and life science instrumentation markets. Financially, Agilent demonstrated strong operational execution. While net income was significantly impacted by discrete tax benefits in 2019 ($1.071 billion) and a tax charge in 2018, the underlying operational performance was robust. The company continued its commitment to shareholder returns through share repurchases, buying back approximately $723 million of its stock under its new repurchase program, and by declaring dividends. Agilent maintains a healthy balance sheet with $1.382 billion in cash and cash equivalents, supporting its ongoing investments in R&D and strategic acquisitions.

Agilent Technologies, Inc. reported solid revenue growth in fiscal year 2018, driven by increases across all three of its business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company's net revenue reached $4.914 billion, a 10% increase from the prior year, supported by favorable foreign currency movements and strategic acquisitions. Despite revenue growth, net income saw a significant decrease due to a large discrete tax charge related to the U.S. Tax Cuts and Jobs Act. The company remains focused on product differentiation, enhancing customer experience, and expanding its operating margin through continued investment in research and development and strategic acquisitions, such as ACEA Biosciences Inc. Financially, Agilent maintained a strong liquidity position with substantial cash and cash equivalents. The company also demonstrated a commitment to shareholder returns through its dividend and share repurchase programs, announcing a new $1.75 billion repurchase program. Looking ahead, Agilent anticipates continued growth, although it expects foreign currency to have a negative impact on revenue in the upcoming year, which it aims to offset with contributions from recent acquisitions. The company is navigating a dynamic market, emphasizing innovation and operational efficiency to maintain its competitive edge.

Agilent Technologies, Inc. reported solid revenue growth in fiscal year 2017, with total net revenue increasing by 6% to $4.47 billion. This growth was driven by strong performance across its three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company saw particularly robust growth in its Diagnostics and Genomics segment (up 9%) and Agilent CrossLab segment (up 8%), indicating increasing demand for its solutions in healthcare and lab services. Looking ahead, Agilent expressed optimism for growth opportunities, especially in the diagnostics market, while also acknowledging potential macroeconomic and political uncertainties that might moderate revenue projections in certain areas for fiscal year 2018. The company continues to focus on operational improvements and returning value to shareholders through dividends and share repurchases, demonstrating a balanced approach to growth and shareholder returns.

Agilent Technologies, Inc.'s 2016 10-K filing reveals a company focused on life sciences, diagnostics, and applied chemical markets. The company generated $4.2 billion in net revenue for the fiscal year ended October 31, 2016, with 70% of that revenue coming from international markets. Agilent operates through three primary segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company is strategically investing in R&D and making targeted acquisitions to drive growth and expand its offerings in areas like cell analysis and core laboratory management. Despite a challenging economic environment and unfavorable currency movements impacting revenue by approximately 2%, Agilent demonstrated resilience with a 4% increase in net revenue year-over-year. Key growth drivers included the pharmaceutical and biotechnology markets, alongside solid performance in the food and environmental sectors. The company is committed to returning value to shareholders through dividends and share repurchases, and is focused on improving operating margins through operational efficiencies and strategic initiatives.

Agilent Technologies, Inc. reported flat net revenue of $4.038 billion for the fiscal year ended October 31, 2015, compared to the prior year. This performance was significantly impacted by an unfavorable foreign currency movement of approximately 6 percentage points. The company experienced a decrease in revenue for its Life Sciences and Applied Markets segment due to softness in chemical and energy markets and a decline in the life sciences research market, partially offset by growth in the pharmaceutical and biotechnology sectors. The Diagnostics and Genomics segment revenue remained flat, despite strong demand in nucleic acid solutions and genomics, due to an unfavorable currency impact. Agilent CrossLab, its consumables and services segment, saw a 2% revenue increase, driven by aftermarket services and consumables, though also affected by currency headwinds. Despite flat revenue, Agilent reported a significant increase in net income from continuing operations to $438 million in 2015, up from $232 million in 2014. This improvement was driven by higher gross margins, resulting from factors like favorable product mix and operational efficiencies, and reduced R&D and SG&A expenses (excluding certain items). The company also completed the separation of its electronic measurement business, Keysight Technologies, Inc., on November 1, 2014. Agilent continued its capital return program by repurchasing shares and declaring dividends. However, the company disclosed a material weakness in internal controls over financial reporting related to the accounting for income taxes.

Agilent Technologies, Inc. reported its fiscal year 2014 results, marked by a significant strategic separation of its electronic measurement business into a new entity, Keysight Technologies, Inc., which was completed on November 1, 2014. This separation effectively reshaped Agilent's operational focus towards its life sciences, diagnostics, and chemical analysis segments. The company reported total net revenue of $6.981 billion, a 3% increase year-over-year, with notable growth in the Life Sciences and Diagnostics (up 3%) and Chemical Analysis (up 5%) businesses, while the Electronic Measurement business saw a 2% increase before its spin-off. Management highlighted positive order growth across all segments, driven by demand in pharmaceutical, biotechnology, food safety, and environmental markets, alongside improvements in communications and semiconductor test markets within the electronic measurement segment. Agilent also announced its decision to exit the Nuclear Magnetic Resonance (NMR) business in the fourth quarter of fiscal 2014, incurring approximately $68 million in related charges. Financially, the company generated operating cash flow of $711 million. While net income decreased to $504 million from $724 million in fiscal 2013, this was influenced by pre-separation costs of $191 million and debt redemption expenses. The company maintained a strong balance sheet with $3.028 billion in cash and cash equivalents. Key strategic moves and operational adjustments position Agilent for continued focus on its core measurement and analytical solutions businesses moving forward.

Agilent Technologies, Inc. reported a decrease in net revenue for fiscal year 2013 to $6.78 billion from $6.86 billion in fiscal year 2012. This decline was primarily driven by a significant 13% drop in revenue from the Electronic Measurement segment, impacted by the loss of a key customer and soft demand in general purpose markets. The Life Sciences and Diagnostics segment showed resilience with 16% revenue growth, largely attributed to the acquisition of Dako, while the Chemical Analysis segment saw a modest 2% increase. A major strategic development announced in September 2013 was the plan to separate into two publicly traded companies: one retaining the Agilent name for life sciences, diagnostics, and chemical analysis businesses, and the other comprising the electronic measurement business, expected to be completed by early November 2014. The company also reported a decrease in net income to $724 million in fiscal 2013 from $1.15 billion in fiscal 2012. This was influenced by higher operating expenses, including those related to the Dako acquisition and restructuring costs. Despite these challenges, Agilent maintained a strong cash position, with cash and cash equivalents at $2.68 billion as of October 31, 2013. The company continues to focus on innovation and operational efficiency, with R&D expenditures remaining significant.

Agilent Technologies, Inc. (Agilent) has reported its fiscal year 2012 results, showcasing a company actively pursuing growth through strategic acquisitions and organic development. The company has expanded its operational segments to four: Life Sciences, Chemical Analysis, Diagnostics and Genomics, and Electronic Measurement. A significant event during the year was the acquisition of Dako A/S for approximately $2.143 billion, which is expected to bolster Agilent's presence in the diagnostics market, particularly in cancer diagnostics and molecular diagnostics. Financially, Agilent demonstrated revenue growth, driven largely by the Dako acquisition, with total net revenue reaching $6.858 billion. Net income also saw an increase to $1.153 billion. The company maintains a strong liquidity position with substantial cash and cash equivalents. Despite the challenging global economic environment, Agilent continues to invest in research and development to foster innovation and maintain its competitive edge across its diverse business segments. The company is strategically positioned to leverage its broad portfolio and global infrastructure to drive future growth, with a stated focus on optimizing operations and introducing new technologies.

Agilent Technologies, Inc. reported a strong fiscal year ended October 31, 2011, with net revenue increasing by 22% to $6.615 billion. This growth was significantly bolstered by the acquisition of Varian, Inc. in May 2010, which contributed approximately 5 percentage points to the revenue increase after accounting for divested businesses. The company's net income saw a substantial rise to $1.012 billion from $684 million in the prior year, reflecting improved operating results and effective management of expenses. The company's performance was driven by broad-based improvements across its three key business segments: Life Sciences, Chemical Analysis, and Electronic Measurement. The Life Sciences segment experienced a 21% revenue increase, supported by strong performance in LC-MS and genomics products, while the Chemical Analysis segment grew 27%, driven by demand in petrochemical and food safety markets. The Electronic Measurement segment saw a 19% revenue increase, with strong performance in both general-purpose and communications test markets. Agilent ended the fiscal year with a healthy cash position of $3.5 billion, indicating sound financial management. The company continued its investment in research and development, demonstrating a commitment to innovation and future growth. Looking ahead, Agilent remains focused on integrating its acquisitions, driving cost synergies, and expanding its market presence, particularly in emerging markets.

Agilent Technologies, Inc. reported strong revenue growth in fiscal year 2010, driven by the acquisition of Varian, Inc. and a recovery in its key markets following the economic downturn of 2009. The company's net revenue increased by 21% to $5.44 billion, with significant contributions from its Life Sciences and Chemical Analysis segments, bolstered by the Varian acquisition. Agilent also completed the divestiture of its Network Solutions Division and Hycor Biomedical, streamlining its business focus. The company ended the fiscal year with a healthy cash position of $2.65 billion, although it also carried approximately $2.19 billion in long-term debt, much of which was refinanced during the year with new senior notes. Despite the acquisition-related integration efforts and ongoing economic uncertainties, Agilent demonstrated improved profitability and operational efficiency, as reflected in a return to net income after a loss in the prior year.

Agilent Technologies, Inc. filed its 10-K for the fiscal year ended October 31, 2009, reporting a challenging year marked by a significant revenue decline of 22% to $4.48 billion, primarily due to the global economic downturn. This resulted in a net loss of $31 million, a reversal from the $693 million net income in the prior year. The company implemented substantial restructuring activities, including workforce reductions, aiming for annual savings of approximately $525 million. Despite the weak financial performance, Agilent continued its strategic initiatives, notably the planned $1.5 billion acquisition of Varian, Inc., which was approved by Varian shareholders and awaited regulatory approvals. The company's liquidity remained solid, with cash and cash equivalents increasing to $2.48 billion by year-end. Agilent operates across three main segments: Electronic Measurement, Bio-analytical Measurement, and Semiconductor and Board Test. All segments experienced revenue declines in fiscal year 2009. The Electronic Measurement segment saw a 30% revenue drop, Bio-analytical Measurement decreased by 6%, and Semiconductor and Board Test declined by a significant 54%. Management noted signs of market stabilization towards the end of the fiscal year but anticipated a gradual recovery. The company also announced changes to its reporting segments for fiscal year 2010, consolidating electronic measurement and semiconductor and board test into a single segment, and splitting the bio-analytical measurement segment into Life Sciences and Chemical Analysis.

Agilent Technologies, Inc. reported net revenue of $5.77 billion for the fiscal year ended October 31, 2008, marking a 7% increase from the prior year, driven by strong performance in its bio-analytical measurement business, which saw a 14% revenue increase. The electronic measurement business experienced a more modest 2% revenue growth, impacted by a slight decline in the general purpose test market due to weakness in computer and semiconductor sectors. Despite a challenging macroeconomic environment and financial market disruptions, the company demonstrated resilience, with net income from continuing operations at $693 million, up from $638 million in the previous year. Agilent maintained a solid financial position with $1.4 billion in cash and cash equivalents at year-end. The company continued its strategic investments in R&D, totaling $704 million, to support innovation. Management highlighted ongoing efforts to manage costs and optimize operations, including headcount reductions and a focus on key growth markets like food safety and wireless technologies.

Agilent Technologies, Inc. reported a solid fiscal year 2007, with total net revenue increasing by 9% to $5.42 billion, driven by strong performance in its Bio-analytical Measurement segment which saw a 20% revenue increase. The Electronic Measurement segment also grew, albeit at a slower pace of 3%. The company generated $969 million in operating cash flow, ending the year with $1.83 billion in cash and cash equivalents. Key strategic initiatives in fiscal 2007 included the acquisition of Stratagene Corporation to bolster its life sciences offerings and the completion of a $2.0 billion stock repurchase program. Looking ahead, Agilent aims to outpace market growth through increased market share, new product introductions, and strategic acquisitions.

Agilent Technologies, Inc. reported significant strategic progress in fiscal year 2006, marked by the successful divestiture of its semiconductor products and semiconductor test solutions businesses. This strategic shift positions the company with a more focused portfolio on its core bio-analytical and electronic measurement solutions. Revenue from continuing operations saw a 6% increase year-over-year, reaching $4.97 billion, driven by growth in both the bio-analytical (9%) and electronic measurement (5%) segments. The company's financial performance in 2006 was significantly bolstered by substantial gains from these divestitures, including the sale of its semiconductor products business for approximately $2.6 billion and the distribution of its semiconductor test solutions business, which had an aggregate market value of $840 million. These events, along with a gain from the sale of its Lumileds investment, contributed to a net income of $3.31 billion for the year. Agilent also actively returned capital to shareholders, completing a $4.466 billion stock repurchase program and initiating another for up to $2 billion. Looking ahead, Agilent aims to leverage its more stable, less cyclical operating model for higher sustainable growth through market share gains and complementary acquisitions, while navigating economic uncertainties.

Agilent Technologies, Inc. filed its 2006 10-K on January 17, 2006, reporting on its fiscal year ending October 31, 2005. The company experienced flat total net revenue of $5.1 billion, with growth in its bio-analytical measurement business (up 7%) and electronic measurement business, offset by a decline in its semiconductor test solutions business (down 25%). Net income saw a decrease of 11% to $327 million, impacted by a $48 million tax charge related to repatriated foreign earnings. Significant strategic actions were undertaken during the year, including the completion of the divestiture of the semiconductor products business for approximately $2.6 billion and a $4.466 billion stock repurchase program. The company also initiated cost reduction plans to reduce infrastructure costs by over $450 million and plans to spin off its semiconductor test solutions business in 2006. Agilent maintains a strong financial position with $2.3 billion in cash and cash equivalents and short-term investments, and generated $643 million in operating cash flow. A notable event was the restatement of the 2004 financial statements due to an error in accounting for income taxes, which reduced the provision for income taxes by $20 million and increased net income by $20 million, or $0.04 per diluted share. This restatement highlights the company's commitment to accurate financial reporting and the robustness of its internal controls.

Agilent Technologies, Inc. reported solid financial performance for the fiscal year ended October 31, 2004, marking a significant recovery from the prior two years. Net revenue increased by 19% to $7.18 billion, driven by growth across all four business segments, particularly Test and Measurement and Life Sciences and Chemical Analysis. The company successfully reduced operating expenses as a percentage of revenue, benefiting from ongoing restructuring efforts and cost controls, which resulted in a return to profitability with income from continuing operations of $349 million. Agilent maintained a strong liquidity position, ending the year with $2.3 billion in cash and cash equivalents, and focused on investing in new product development and strategic opportunities. The company experienced a notable slowdown in its Semiconductor Products and Automated Test businesses in the latter half of the year due to customer inventory build-up, but overall performance demonstrated resilience and strategic repositioning. Agilent continued its global expansion, with international revenue accounting for 69% of total net revenue. Key strategic initiatives included streamlining IT systems and managing its cost structure through outsourcing and operational efficiencies, positioning the company for sustained growth. Investors should note the company's significant restructuring charges incurred over the past few years, which are impacting current operations but are intended to drive future efficiency. While the company has returned to profitability, the market conditions in its semiconductor-related businesses remain a key factor to monitor. Agilent's focus on innovation in its Life Sciences and Chemical Analysis segments, alongside improvements in its core Test and Measurement offerings, suggests a diversified approach to market challenges.

Agilent Technologies, Inc. reported a challenging fiscal year ended October 31, 2003, marked by a significant net loss of $2.06 billion. This loss was heavily influenced by a $1.4 billion tax valuation allowance charge related to net deferred tax assets, as well as substantial restructuring and asset impairment charges totaling $372 million across its various plans aimed at reducing costs and returning the company to profitability. Despite the overall loss, the company saw signs of an upturn in its end markets, particularly in the fourth quarter, with orders reaching their highest level since Q1 2001. The company continued to manage its expenses diligently, reducing its workforce by approximately 15,000 employees since April 2001 and consolidating facilities to improve operational efficiency. The company's performance varied across its segments. The Test and Measurement segment experienced a revenue decline, reflecting the continued weakness in telecommunications markets. The Semiconductor Products segment showed some growth, driven by demand in personal systems and networking markets, although it faced pricing pressures. The Automated Test segment demonstrated improvement, returning to profitability in the latter half of the year, supported by growth in semiconductor test markets. The Life Sciences and Chemical Analysis segment reported revenue growth, bolstered by Asian economic development and new product introductions. Looking ahead, Agilent aims to sustain profitability by maintaining its reduced cost structure and leveraging an expected gradual economic recovery. The company's liquidity remained strong with significant cash and cash equivalents, though its credit ratings were downgraded to speculative grade by major agencies, impacting future borrowing costs.

Agilent Technologies, Inc.'s 2002 10-K filing reveals a challenging year marked by a significant revenue decline and a substantial net loss. The company experienced a 28% drop in net revenue to $6.01 billion, primarily driven by weakness in the telecommunications, semiconductor, and electronics industries, which led to a net loss of $1.03 billion. This performance is largely attributed to a prolonged economic downturn that began in 2001. In response to these conditions, Agilent implemented significant restructuring efforts, including workforce reductions totaling approximately 8,000 employees, and plans for further cost reductions. The company's strategic focus remains on its three core businesses: test and measurement, semiconductor products, and life sciences and chemical analysis, with an emphasis on developing new products and technologies to drive future growth. Despite the headwinds, Agilent maintains a strong balance sheet with significant cash and cash equivalents, positioning it to navigate the current economic climate and invest in its long-term strategic priorities.

Agilent Technologies, Inc. filed an amended 10-K for the fiscal year ended October 31, 2001, primarily to correct an omission of a financial statement page. The core financial performance for the year showed a net loss from continuing operations of $406 million, a significant decrease from the $672 million profit in the prior year. This decline was primarily driven by increased costs and expenses, particularly in cost of products, R&D, and SG&A, outpacing revenue growth. A substantial positive impact came from the gain on the sale of discontinued operations, specifically the Healthcare Solutions Group to Philips, which contributed $646 million after taxes, leading to a reported net earnings of $174 million for the fiscal year. Despite the operational loss from continuing segments, the company's balance sheet indicates a solid liquidity position with $1.17 billion in cash and cash equivalents. However, accounts receivable and inventory saw declines compared to the previous year, suggesting potential shifts in sales cycles or inventory management. The company also incurred significant restructuring charges in 2001, reflecting efforts to adapt to economic conditions. Investors should note the substantial debt offering of $1.15 billion in convertible debentures in November 2001, which provides financial flexibility but also introduces potential dilution and future interest obligations.

Agilent Technologies, Inc. reported total net revenue of $8.4 billion for the fiscal year ended October 31, 2001, a decrease of 10.3% from the prior year, reflecting a significant economic downturn impacting the communications, electronics, and semiconductor industries. The company experienced a net loss from continuing operations of $406 million, a stark contrast to the $672 million in earnings from continuing operations in fiscal year 2000. This downturn primarily affected the Test and Measurement and Semiconductor Products segments. Offsetting some of the operational challenges, Agilent completed the sale of its healthcare solutions business for $1.7 billion, resulting in a substantial after-tax gain of $646 million from discontinued operations. The company also took significant steps to manage costs, including workforce reductions and restructuring initiatives. Despite the challenging economic environment, Agilent maintained a strong liquidity position with $1.17 billion in cash and cash equivalents at year-end and secured additional financing through a $1.15 billion convertible debenture offering.

Agilent Technologies, Inc. filed its 2000 Annual Report (10-K) on January 17, 2001, detailing its business operations, financial performance, and strategic outlook. The company, a spin-off from Hewlett-Packard, operates primarily in measurement and chemical analysis sectors, serving diverse markets including life sciences, diagnostics, and applied chemical industries. Investors should note Agilent's focus on innovation and its position within rapidly evolving technological fields.